Stocktoria
MYOMO, INC. MYO
MYOMO, INC. (MYO) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $40.9M at a -38.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.68 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.497 |
| Retained earnings / assets | -3.072 |
| EBIT / assets | -0.373 |
| Equity / liabilities | 0.419 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MYO | MYOMO, INC. | 3/9 | -8.82 | — | +25.7% |
| APT | ALPHA PRO TECH LTD | 4/9 | 12.4 | 16.1 | +2.3% |
| LFWD | Lifeward Ltd. | 4/9 | — | — | -14.1% |
| ZJYL | Jin Medical International Ltd. | 4/9 | 5.16 | 15.7 | -12% |
| MLSS | MILESTONE SCIENTIFIC INC. | 2/9 | — | — | — |
| FEED | ENvue Medical, Inc. | 2/9 | -6.2 | — | — |
| CLGN | CollPlant Biotechnologies Ltd | 3/9 | — | — | — |
About MYOMO, INC.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
FAQ
Is MYO financially healthy?
MYOMO, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MYO pay a dividend?
No, MYOMO, INC. does not currently pay a dividend.
How profitable is MYO?
In FY2025, MYOMO, INC. had a net margin of -38.1% and a return on equity of -136.6%.
What is the analyst price target for MYO?
The average Wall-Street price target for MYOMO, INC. is $4.42, about 190.8% above the recent price, from 5 analysts.
Is MYO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on MYOMO, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.